Cargando…

The Efficacy of a 3β-Hydroxysteroid Dehydrogenase Inhibitor for the Termination of Mid-Term Pregnancies in Dogs

SIMPLE SUMMARY: The medical termination of unwanted pregnancies in dogs is practiced throughout the world for many reasons, including at the request of animal owners. For these procedures, it is advised to use rapidly effective drugs with minimal side effects. In this study, we investigated trilosta...

Descripción completa

Detalles Bibliográficos
Autores principales: Binli, Firdevs, İnan, İpek, Büyükbudak, Fatih, Gram, Aykut, Kaya, Duygu, Liman, Narin, Aslan, Selim, Fındık, Murat, Ay, Serhan Serhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495022/
https://www.ncbi.nlm.nih.gov/pubmed/36139334
http://dx.doi.org/10.3390/ani12182475
_version_ 1784793921301250048
author Binli, Firdevs
İnan, İpek
Büyükbudak, Fatih
Gram, Aykut
Kaya, Duygu
Liman, Narin
Aslan, Selim
Fındık, Murat
Ay, Serhan Serhat
author_facet Binli, Firdevs
İnan, İpek
Büyükbudak, Fatih
Gram, Aykut
Kaya, Duygu
Liman, Narin
Aslan, Selim
Fındık, Murat
Ay, Serhan Serhat
author_sort Binli, Firdevs
collection PubMed
description SIMPLE SUMMARY: The medical termination of unwanted pregnancies in dogs is practiced throughout the world for many reasons, including at the request of animal owners. For these procedures, it is advised to use rapidly effective drugs with minimal side effects. In this study, we investigated trilostane, which decreases progesterone levels, for its efficacy in terminating mid-term pregnancies in dogs, as well as potential side effects. Although trilostane is not a standalone alternative for the termination of pregnancy in dogs, it has been determined that its combined use with another medical agent of known efficacy reduces both the abortion time and potential side effects. Further studies investigating an increased frequency of administration rather than the administration dose could contribute to determining the efficacy of trilostane in dogs. ABSTRACT: Progesterone (P4) is the only hormone needed to maintain pregnancy in dogs. Therefore, a competitive inhibitor of 3β-hydroxysteroid dehydrogenase (3β-HSD) could be a safe and effective option to terminate pregnancy by inhibiting P4 synthesis. To address this hypothesis, we investigated the efficacy of trilostane (TRL), a competitive inhibitor of 3β-HSD, in terminating pregnancy in dogs. Twenty-one dogs between days 30 and 38 of pregnancy were randomly assigned to one of two treatment groups (trilostane (TRL) and aglepristone (AGL)) and an untreated control (CON) group (n = 7 dogs each). Fetal heart rates (FHRs) (measured at 12 h intervals) and serum P4 concentrations (measured at 6 h intervals) were evaluated. The pregnancy termination rates were 0% and 100% in the TRL and AGL groups, respectively. The decrease in the FHR in the TRL and AGL groups was significantly lower than that observed in the CON group. There was a marked decrease in P4 concentrations in the TRL group 6, 54, and 102 h after the initiation of treatment. The luteal expression of StAR appeared to be weaker in the AGL group than the CON group. In conclusion, although a treatment-induced decrease was observed in plasma P4 concentrations, a seven-day TRL treatment alone was not effective in terminating pregnancies. Further studies are needed on the effects of the prolonged administration of TRL with varying doses and frequencies for the termination of mid-term pregnancy in dogs.
format Online
Article
Text
id pubmed-9495022
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94950222022-09-23 The Efficacy of a 3β-Hydroxysteroid Dehydrogenase Inhibitor for the Termination of Mid-Term Pregnancies in Dogs Binli, Firdevs İnan, İpek Büyükbudak, Fatih Gram, Aykut Kaya, Duygu Liman, Narin Aslan, Selim Fındık, Murat Ay, Serhan Serhat Animals (Basel) Article SIMPLE SUMMARY: The medical termination of unwanted pregnancies in dogs is practiced throughout the world for many reasons, including at the request of animal owners. For these procedures, it is advised to use rapidly effective drugs with minimal side effects. In this study, we investigated trilostane, which decreases progesterone levels, for its efficacy in terminating mid-term pregnancies in dogs, as well as potential side effects. Although trilostane is not a standalone alternative for the termination of pregnancy in dogs, it has been determined that its combined use with another medical agent of known efficacy reduces both the abortion time and potential side effects. Further studies investigating an increased frequency of administration rather than the administration dose could contribute to determining the efficacy of trilostane in dogs. ABSTRACT: Progesterone (P4) is the only hormone needed to maintain pregnancy in dogs. Therefore, a competitive inhibitor of 3β-hydroxysteroid dehydrogenase (3β-HSD) could be a safe and effective option to terminate pregnancy by inhibiting P4 synthesis. To address this hypothesis, we investigated the efficacy of trilostane (TRL), a competitive inhibitor of 3β-HSD, in terminating pregnancy in dogs. Twenty-one dogs between days 30 and 38 of pregnancy were randomly assigned to one of two treatment groups (trilostane (TRL) and aglepristone (AGL)) and an untreated control (CON) group (n = 7 dogs each). Fetal heart rates (FHRs) (measured at 12 h intervals) and serum P4 concentrations (measured at 6 h intervals) were evaluated. The pregnancy termination rates were 0% and 100% in the TRL and AGL groups, respectively. The decrease in the FHR in the TRL and AGL groups was significantly lower than that observed in the CON group. There was a marked decrease in P4 concentrations in the TRL group 6, 54, and 102 h after the initiation of treatment. The luteal expression of StAR appeared to be weaker in the AGL group than the CON group. In conclusion, although a treatment-induced decrease was observed in plasma P4 concentrations, a seven-day TRL treatment alone was not effective in terminating pregnancies. Further studies are needed on the effects of the prolonged administration of TRL with varying doses and frequencies for the termination of mid-term pregnancy in dogs. MDPI 2022-09-19 /pmc/articles/PMC9495022/ /pubmed/36139334 http://dx.doi.org/10.3390/ani12182475 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Binli, Firdevs
İnan, İpek
Büyükbudak, Fatih
Gram, Aykut
Kaya, Duygu
Liman, Narin
Aslan, Selim
Fındık, Murat
Ay, Serhan Serhat
The Efficacy of a 3β-Hydroxysteroid Dehydrogenase Inhibitor for the Termination of Mid-Term Pregnancies in Dogs
title The Efficacy of a 3β-Hydroxysteroid Dehydrogenase Inhibitor for the Termination of Mid-Term Pregnancies in Dogs
title_full The Efficacy of a 3β-Hydroxysteroid Dehydrogenase Inhibitor for the Termination of Mid-Term Pregnancies in Dogs
title_fullStr The Efficacy of a 3β-Hydroxysteroid Dehydrogenase Inhibitor for the Termination of Mid-Term Pregnancies in Dogs
title_full_unstemmed The Efficacy of a 3β-Hydroxysteroid Dehydrogenase Inhibitor for the Termination of Mid-Term Pregnancies in Dogs
title_short The Efficacy of a 3β-Hydroxysteroid Dehydrogenase Inhibitor for the Termination of Mid-Term Pregnancies in Dogs
title_sort efficacy of a 3β-hydroxysteroid dehydrogenase inhibitor for the termination of mid-term pregnancies in dogs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495022/
https://www.ncbi.nlm.nih.gov/pubmed/36139334
http://dx.doi.org/10.3390/ani12182475
work_keys_str_mv AT binlifirdevs theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT inanipek theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT buyukbudakfatih theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT gramaykut theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT kayaduygu theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT limannarin theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT aslanselim theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT fındıkmurat theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT ayserhanserhat theefficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT binlifirdevs efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT inanipek efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT buyukbudakfatih efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT gramaykut efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT kayaduygu efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT limannarin efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT aslanselim efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT fındıkmurat efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs
AT ayserhanserhat efficacyofa3bhydroxysteroiddehydrogenaseinhibitorfortheterminationofmidtermpregnanciesindogs